Search

Coherus Oncology Inc

Cerrado

SectorSanidad

1.11 -0.89

Resumen

Variación precio

24h

Actual

Mínimo

1.12

Máximo

1.1400000000000001

Métricas clave

By Trading Economics

Ingresos

-21M

-59M

Ventas

2M

14M

P/B

Media del Sector

3.509

55.725

BPA

-0.22

Margen de beneficios

-412.092

Empleados

144

EBITDA

3.7M

-30M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+585.84% upside

Dividendos

By Acuity

Próximas Ganancias

5 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-10M

212M

Apertura anterior

2

Cierre anterior

1.11

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

95 / 339 Clasificación en Healthcare

Coherus Oncology Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

25 sept 2026, 20:07 UTC

Coherus Oncology Inc shares fell sharply, closing at their lowest point of the day, continuing a trend of lower performance over the past four sessions.

24 sept 2026, 23:50 UTC

Coherus Oncology Inc saw a modest increase in after-market trading, rebounding from four consecutive sessions of declines.

23 sept 2026, 19:51 UTC

News

Coherus Oncology Inc shares fell sharply as the company appointed Oppenheimer & Co. to advise on the sale of its Legacy BioSim Assets.

22 sept 2026, 20:01 UTC

Coherus Oncology Inc shares fell sharply, reversing from an early high and currently trading significantly below Monday's close and its 20-day moving average.

21 sept 2026, 20:01 UTC

Coherus Oncology Inc is trading higher, rebounding from an early low and peaking in the early afternoon, currently above its 20-day moving average.

18 sept 2026, 20:02 UTC

Coherus Oncology Inc is advancing sharply, achieving its highest cumulative return of the day, despite remaining below its 20-day moving average.

17 sept 2026, 20:01 UTC

Coherus Oncology Inc is rising, reaching a peak return today, although it remains below its 20-day moving average and near the lower end of its one-month range.

16 sept 2026, 19:03 UTC

Coherus Oncology Inc shares fell sharply, continuing a notable decline since Tuesday's close and remaining well below their 20-day moving average.

15 sept 2026, 20:01 UTC

Coherus Oncology Inc shares are trading lower amid negative market sentiment following a significant drop in the NY Empire State Manufacturing Index for September.

14 sept 2026, 20:08 UTC

Coherus Oncology Inc shares are higher during Monday's session, continuing a significant advance since Friday's close amid broader market trends and inflation concerns.

9 sept 2026, 20:07 UTC

Coherus Oncology Inc's shares are lower today, continuing a downward trend since Tuesday. The stock reached a session low amid broader market weakness.

2 sept 2026, 19:46 UTC

Coherus Oncology Inc. shares are higher today, maintaining momentum since Tuesday's close and remaining above the 20-day moving average.

1 sept 2026, 20:09 UTC

Coherus Oncology Inc is gaining as the Biotechnology sub-sector shows significant upward movement. The stock remains stable, finishing near its one-month range high.

31 ago 2026, 20:02 UTC

News

Coherus Oncology shares are lower despite announcing participation in upcoming investor conferences and plans to enhance sales of its PD-1 inhibitor, LOQTORZI.

28 ago 2026, 23:06 UTC

News

Coherus Oncology's $50 million common share offering pressures shares lower in after-market trading, marking a pullback from recent highs.

27 ago 2026, 19:46 UTC

Coherus Oncology Inc shares are higher today, continuing an upward trend over three consecutive sessions. The stock remains above its 20-day moving average.

26 ago 2026, 19:35 UTC

Coherus Oncology Inc is trading higher, maintaining upward momentum since Tuesday's close and performing well above its 20-day moving average.

25 ago 2026, 20:07 UTC

Coherus Oncology Inc. shares are trading roughly flat amid easing Treasury yields, which typically support equities and enhance investor sentiment toward risk assets.

24 ago 2026, 20:04 UTC

Coherus Oncology Inc shares are lower today, continuing a broader market decline. No specific company news has been identified to explain the movement.

21 ago 2026, 20:01 UTC

Correlated Moves

Coherus BioSciences Inc. shares are higher today, reflecting positive momentum in the biotechnology sector and broader trends in related equities since Thursday's close.

20 ago 2026, 23:16 UTC

Coherus BioSciences Inc shares are higher in after-market trading, reflecting modest gains despite broader market pressures and no specific company news identified.

19 ago 2026, 20:02 UTC

Coherus BioSciences remains roughly flat during Wednesday's session, with no specific news identified. The broader market also showed little change.

18 ago 2026, 23:26 UTC

Coherus BioSciences Inc is trading higher in after-market hours, despite broader market pressures from rising bond yields and elevated oil prices.

17 ago 2026, 23:41 UTC

News

Coherus BioSciences announced a special dividend of contingent value rights, boosting shares in after-market trading following the company's strategic asset sale initiative.

14 ago 2026, 19:31 UTC

Coherus BioSciences Inc shares are higher today, despite no specific news. Broader market sentiment includes concerns over disappointing U.S. retail sales data.

13 ago 2026, 19:46 UTC

Social Media

Coherus BioSciences Inc shares are lower, extending a four-session decline. Despite social media optimism, the stock remains below its 20-day moving average.

12 ago 2026, 23:01 UTC

Coherus BioSciences Inc shares are trading higher in after-market hours, despite recent declines and no specific news to explain the movement.

11 ago 2026, 19:36 UTC

Coherus BioSciences Inc shares are lower amid broader market sentiment influenced by geopolitical tensions and upcoming U.S. inflation reports. No specific company news identified.

10 ago 2026, 23:31 UTC

Coherus BioSciences Inc shares are higher in after-market trading, advancing from a low of 0.81% to a high of 3.25% since Monday's close.

8 ago 2026, 00:01 UTC

Coherus BioSciences Inc shares rose in after-market hours, recovering from earlier volatility and settling higher since Friday's close despite no specific news identified.

Comparación entre iguales

Cambio de precio

Coherus Oncology Inc previsión

Precio Objetivo

By TipRanks

585.84% repunte

Estimación a 12 Meses

Media 7.75 USD  585.84%

Máximo 10 USD

Mínimo 4 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Coherus Oncology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

4

Comprar

0

Mantener

0

Vender

Sentimiento

By Acuity

95 / 339 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.